Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.
The purine analogue, fludarabine, is of proven efficacy in the treatment of lymphoid malignancies. The drug appears to be well tolerated with minimal side-effects, and few toxicities have been observed. A case of myelodysplasia occurring after therapy with fludarabine is presented and its implications are discussed.
Frewin
R J
RJ
Department of Haematology, Southampton University Hospitals NHS Trust, UK.
Provan
D
D
Smith
A G
AG
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity*; D002898:Chromosomes, Human, Pair 8; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D009503:Neutropenia / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014314:Trisomy / Q000235:genetics; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine